Evidence map›Paper›PMID 37308958›Full record

ArticleAnnals of clinical microbiology and antimicrobials2023

Evolution of carbapenem resistance in klebsiella pneumoniae and escherichia coli carrying bla

Qiong Zhao, Longhua Sha, Zhaomeng Wu, Lixue Meng, Feixiang Yang, Lingling Wu, Chunfang Yu, Hua Zhang, Jingdan Yu, Zhixiong Jin

Open access · goldAbstract read
In one paragraph

Article in Annals of clinical microbiology and antimicrobials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. In vitro activity of the novel β-lactamase inhibitor FL058 combined with meropenem against KPC- or NDM-producing enterobacterales and Pseudomonas aeruginosa.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Article
  2. ACS omega · 2025
    Article
  3. Characterization ofFrontiers in cellular and infection microbiology · 2025
    Article
  4. Article
  5. The effects of NDM-5 onFrontiers in microbiology · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Qiong ZhaoDepartment of Microbiology, School of Basic Medical Sciences, Hubei University of Medicine, Hubei, 442000, Shiyan, China.
Longhua ShaDepartment of Microbiology, School of Basic Medical Sciences, Hubei University of Medicine, Hubei, 442000, Shiyan, China.
Zhaomeng WuDepartment of Microbiology, School of Basic Medical Sciences, Hubei University of Medicine, Hubei, 442000, Shiyan, China.
Lixue MengDepartment of Microbiology, School of Basic Medical Sciences, Hubei University of Medicine, Hubei, 442000, Shiyan, China.
Feixiang YangDepartment of Clinical Laboratory, Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Hubei, Shiyan, 442008, China.
Lingling WuDepartment of Clinical Laboratory, Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Hubei, Shiyan, 442008, China.
Chunfang YuDepartment of Microbiology, School of Basic Medical Sciences, Hubei University of Medicine, Hubei, 442000, Shiyan, China.
Hua ZhangDepartment of Clinical Laboratory, Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Hubei, Shiyan, 442008, China. 727326436@qq.com.
Jingdan YuLaboratory Medicine, Wuhan Asia General Hospital, Hubei, Wuhan, 430050, China. 290733118@qq.com.
Zhixiong JinDepartment of Microbiology, School of Basic Medical Sciences, Hubei University of Medicine, Hubei, 442000, Shiyan, China. jzx8801150@126.com.
Hubei University of Medicine · CNDongfeng General Hospital · CNChina National Pharmaceutical Group Corporation (China) · CNWuhan General Hospital of Guangzhou · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntibiotics exert an outstanding selective pressure on bacteria, forcing their chromosomal gene mutations and drug resistance genes to spread. The objective of this study is to evaluate the expression of the New Delhi Metallo-β-Lactamase-1 gene (bla

methodsβ-Lactamase genes (bla

resultsAfter being exposed to different doses of imipenem, the minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) of antimicrobial drugs and bla

conclusionsLow doses of imipenem could press bla

Indexed as

ImipenemKlebsiella pneumoniaeAnti-Bacterial Agentsbeta-LactamasesCarbapenemsEscherichia coliAnti-Bacterial Agentsbeta-lactamase NDM-1beta-LactamasesCarbapenemsImipenembla NDM−1Drug resistanceEscherichia coliImipenemKlebsiella pneumoniaeβ-lactamase

Identifiers

PMID37308958
PMCPMC10262507
OpenAlexW4380366505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.